Arcus Biosciences, Inc. (RCUS) Stock

Arcus Biosciences, Inc. (RCUS) is a Healthcare stock trading at $30.37 (as of 2026-08-21), with a market capitalization of $3.82B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. Its pipeline includes agents such as etrumadenant, zimberelimab, domvanalimab, quemliclustat, and AB521 in early-to-mid clinical development, and it conducts related evaluations through collaborations including with Strata Oncology and AstraZeneca (with BVF Partners).

Understand Arcus Biosciences, Inc.: how it makes money

Arcus Biosciences develops and advances cancer therapies, including Etrumadenant and Zimberelimab, through clinical trials, and it makes money primarily from collaboration and license related activities rather than from commercial product sales.

For a clinical-stage biopharmaceutical company like Arcus, the near-term profit model is driven by collaboration, license, and development services revenue tied to its drug programs, while sustained profitability depends on future clinical progress and approvals.

Revenue by segment (latest quarter)
Collab$0.0B
LicenseDev$0.0B

Business quality (Weak): Clinical-stage focus with very limited revenue in the latest quarter, and a large negative operating margin, so business momentum depends heavily on trial execution and partnership driven income.

Bull case

  • Active clinical development across multiple programs: Pipeline includes Etrumadenant in a Phase 1b/2 trial and Zimberelimab in a Phase 1b trial, with Domvanalimab in Phase 2 development in combination.
  • Revenue mix includes collaboration and licensing: The provided revenue line items show collaboration revenue of 0.03B and license and development services revenue of 0.02B, which can support operations while products are still in trials.

Bear case

  • High operating losses: Operating margin is reported as -788.2 for the period, indicating substantial losses relative to the current revenue level.
  • Trial and development execution risk: Key pipeline programs are in early to mid stage clinical development (Phase 1b and Phase 2), where outcomes and timelines are uncertain.
  • Cost structure concentrated in R&D: Research and Development Staff Percentage is provided as 80.0 percent, which can increase cash burn risk if additional funding or non-dilutive revenue does not keep pace.
Valuation — source: SEC EDGAR (first-party)
Price$30.37
Market Cap$3.82B
Price / Book7.29
Price / Sales16.54
FCF Yield-23.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$247.00M
Net Margin-142.9%
Revenue Growth (YoY)-4.3%
EPS Growth (YoY)4.8%
FCF Growth (YoY)175.0%
Financial Health — source: SEC EDGAR
Altman Z-Score2.59 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGILEAD SCIENCES, INC. ($678.77M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTerry J. Rosen
Employees627
CountryUS
IPO Date2018-03-15

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Akebia Therapeutics, Inc. (AKBA)
  • AnaptysBio, Inc. (ANAB)
  • LifeVantage Corporation (LFVN)
  • Puma Biotechnology, Inc. (PBYI)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Harrow Health, Inc. (HROW)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Vanda Pharmaceuticals Inc. (VNDA)
RCUS earnings history · RCUS institutional & insider holders · RCUS KPIs & operating metrics · RCUS financials · RCUS investor presentations & press releases · RCUS SEC filings · RCUS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.